Trial Profile
Prospective, randomized, investigator-blind trial to evaluate the bacteriologic eradication, safety and tolerability, and pharmacokinetics of different dosages of faropenem medoxomil BID for 10 Days in the treatment of acute otitis media
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2008
Price :
$35
*
At a glance
- Drugs Faropenem medoxomil (Primary)
- Indications Bacterial infections; Otitis media
- Focus Therapeutic Use
- Sponsors Cardiovascular Systems
- 29 Mar 2007 Interim results have been reported.
- 22 Dec 2006 New trial record.